Su Jing, Li Meng-quan, Xu Han, Hu Di
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Zhonghua Yi Xue Za Zhi. 2011 Jul 12;91(26):1837-9.
To compare the efficacy and toxicity of neoadjuvant chemotherapy of docetaxel with paclitaxel plus pirarubicin hydrochloride (THP) and cyclophosphamide (CTX) in locally advanced breast cancer (LABC).
A total of 97 LABC cases were randomly divided into 2 groups: docetaxel group (n = 49, taxotere plus THP & CTX) and paclitaxel group (n = 48, paclitaxel plus THP & CTX). Neoadjuvant chemotherapy had four cycles of 21 days each.
The clinical and pathological complete remission rates of docetaxel group was 28.6% and 26.5% respectively. They were significantly higher than those of paclitaxel group (10.4% and 8.3%). Furthermore the pathological negative rate of regional lymph node in docetaxel group was also significantly higher than that of paclitaxel group (40.6% vs. 12.9%). However, grade III-IV blood system toxic reaction was found in 71.4% cases, grade II-IV liver dysfunction in 53.1% cases and edema in 24.5% cases among docetaxel group. They were higher than those among paclitaxel group (46.9%, 27.1% & 4.2%).
Compared with paclitaxel, the combined regimen of docetaxel plus THP and CTX offers better outcomes for locally advanced breast cancer.
比较多西他赛与紫杉醇联合吡柔比星（THP）及环磷酰胺（CTX）新辅助化疗治疗局部晚期乳腺癌（LABC）的疗效及毒性。
97例LABC患者随机分为2组：多西他赛组（n = 49，多西他赛联合THP及CTX）和紫杉醇组（n = 48，紫杉醇联合THP及CTX）。新辅助化疗共4个周期，每个周期21天。
多西他赛组临床及病理完全缓解率分别为28.6%和26.5%，显著高于紫杉醇组（10.4%和8.3%）。此外，多西他赛组区域淋巴结病理阴性率也显著高于紫杉醇组（40.6%对12.9%）。然而，多西他赛组71.4%的病例出现Ⅲ-Ⅳ级血液系统毒性反应，53.1%的病例出现Ⅱ-Ⅳ级肝功能障碍，24.5%的病例出现水肿，均高于紫杉醇组（46.9%、27.1%及4.2%）。
与紫杉醇相比，多西他赛联合THP及CTX方案治疗局部晚期乳腺癌疗效更佳。
